Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:00:53.557Z.
Calculation as of: 2026-10-06T18:00:53.557Z.
Quote observation: 2026-10-06T17:59:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c4088ee3877f0fa8fb1d478ebd945bbdf3f6f56484e99899685bc9bfb173ee48
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$4.12M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.34M
Price/FCF Ratio
N/A
TTM Avg
63.09
3Y Avg
63.09
5Y Avg
63.09
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $4.02M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.09M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.12M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.20M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.30M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | N/A | 63.09 | 63.09 | 63.09 |
| Evogene Ltd. (EVGN)vs › | $3.68M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.63M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
